Ligand’s Fourth Quarter Financial Results to be Reported February 3rd

About this update from Ligand Pharmaceuticals Incorporated

[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.\n\nFourth Quarter 2020 Earnings Conference Call\n\n\n\nWhat:\n\n\n\nLigand conference call to discuss financial results and provide general business updates\n\n\n\n\n\n\n \n\n\n\n\n\nDate:\n\n\n\nWednesday, February 3, 2021\n\n\n\n\n\n\n \n\n\n\n\n\nTime:\n\n\n\n8:30 a.m. Eastern time (5:30 a.m. Pacific time)\n\n\n\n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n\nDial (833) 540-1167 within the U.S.\n\n\n\n\n\n\nDial (929) 517-0358 outside the U.S.\n\n\n\n\n\n\nConference ID is 6081598\n\n\n\n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n\nLive conference call webcast and replay accessible at www.ligand.com\n\n\n\n\nAbout Ligand Pharmaceuticals\n\nLigand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Protein Expression Technology® is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well...

More updates from Ligand Pharmaceuticals Incorporated